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INTRODUCTION 
The prevalence of cardiometabolic disease including athero-
sclerosis, hypertension, obesity, type 2 diabetes mellitus, and 
the metabolic syndrome is rising dramatically in developed and 
developing countries. Because clustering all known major risk 
factors in one individual, the metabolic syndrome contributes to 
increased mortality from myocardial infarction and stroke (1-3). 
Recently the neurotrophins nerve growth factor (NGF) (4) and 
brain-derived neurotrophic factor (BDNF) (5) were implicated 
in a positive control of various metabolic function, including 
glucose, lipid and energy homeostasis (6,7) as well as in the 
pathogenesis of cardiometabolic diseases (8-14).
 Since its discovery in 1951 by Rita Levi-Montalcini, it is now 
well recognized that NGF is synthesized, stored and, via exo- and 
endocrine pathway, released by submandibular salivary glands 
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In addition to their stimulatory action on neuronal differentiation and survival, a variety of neurotrophic factors, such as nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor, exert metabotrophic effects, 
including  improvement of  glucose, lipid and energy homeostasis. It was recently reported that plasma levels of both NGF and 
BDNF are reduced in patients with advanced metabolic syndrome and with acute coronary syndromes, and that  NGF tissue 
content is decreased in human atherosclerotic coronary arteries. Since NGF and BDNF are synthesized, stored, and released by 
submandibular salivary glands, we investigated the structure and function of these glands. Here we present our scintigraphic and 
echographic results of submandibular glands of patients with advanced stage of  metabolic syndrome:  (i) scintigraphic analy-
sis using the radiotracer (99m)Tc-pertechnetate showed an inhibition of salivary gland excretory activity, and (ii) echographic 
evaluation revealed a parenchymal destruction and a prominent fibrosis of the glands. Both suggestive for the involvement 
of submandibular glands in decreased  secretion of NGF and BDNF as implicated in the pathogenesis of metabolic syndrome. 
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(15-18). It was recently demonstrated that BDNF is also an en-
docrine product of these glands (19,20). Further, a new pathway 
of neuro-immuno-endocrine interactions has been established, 
namely the submandibular gland-cervical sympathetic trunk 
axis; it has important implications for inflammation and tissue
recovery (21-24). 
 We therefore examine both structure and function of sub-
mandibular glands in patients with advanced metabolic syn-
drome. The submandibular gland has been regarded as an 
age-stable organ in spite of reports on its structural changes 
with aging (18). Twenty patients with advanced stage of meta-
bolic syndrome were studied (mean age 45.69 +/– 2.18) and 7 
controls corresponding in age and sex, without a family history 
of diabetes mellitus or premature  coronary atherosclerosis. 
 Quantitative analysis of (99m)Tc-pertechnetate scintigraphy 
has been used in the evaluation of salivary gland function, 
using single head Gamma Camera System, Siemens, Diacam 
1995. 2 mCi (99m)Tc-pertechnetate was injected intrave-
nously (25). The radiopharmaceutical was accumulated in the 
salivary glands and emitted through their channels. Citric acid 
was given orally on the 20th minute to stimulate salivation and 
the salivary gland drainage was visualized. The time-activity 
curves were plotted based on the obtained scintigraphic images 
and the functional status of the salivary gland and its drainage 
capacity  evaluated. From the twenty investigated patients 
with metabolic syndrome, 8 revealed normal fixation of the
radioactive substance and preserved function. In the remaining 
12 patients a low radioactive nuclide fixation was detected.
 Echographic test of the submandibular gland was performed 
by Fukuda ultrasound diagnostic apparatus. The results showed 
statistically significant increase in the size of submandibular
glands as well as echographic data of tissue fibrosis.
 In conclusion, in patients with advance metabolic syndrome, 
the decreased plasma NGF and BDNF levels may in part result 
from submandibular gland dysfunction. Certainly, other tissue 
source of these neurotrophins, such as adipose tissue (see Töre 
and Tunçel, and Sornelli et al in this volume of Biomedical Re-
views), may also be pursuit. Likewise, the presence of mast cells 
in the submandibular gland be evaluated because these cells are 
source of and target for NGF (4,26) and possibly BDNF.
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